The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of STK11 mutations on efficacy of PD-1 inhibition in non-small cell lung cancer (NSCLC) and dependence on KRAS mutation status.
 
Biagio Ricciuti
No Relationships to Disclose
 
Kathryn Cecilia Arbour
Consulting or Advisory Role - AstraZeneca
Travel, Accommodations, Expenses - Iovance Biotherapeutics
 
Jessica Jiyeong Lin
Honoraria - OncLive; Pfizer
Consulting or Advisory Role - C4 Therapeutics; Genentech; Nuvalent, Inc.
Research Funding - Hengrui Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Natalie Vokes
No Relationships to Disclose
 
Amir Vajdi Hoojghan
No Relationships to Disclose
 
Yvonne Y. Li
Stock and Other Ownership Interests - Editas Medicine; g.Root Biomedical Services; Regenxbio
 
Andrew D. Cherniack
Employment - LabCorp (I)
Stock and Other Ownership Interests - Merck
Research Funding - Bayer
 
Gonzalo Recondo
Consulting or Advisory Role - Amgen; Pfizer; Roche
Travel, Accommodations, Expenses - AstraZeneca; Pfizer
 
Giuseppe Lamberti
No Relationships to Disclose
 
Deepti Venkatraman
No Relationships to Disclose
 
Hira Rizvi
No Relationships to Disclose
 
Jacklynn V. Egger
No Relationships to Disclose
 
Andrew J. Plodkowski
No Relationships to Disclose
 
Sara Khosrowjerdi
No Relationships to Disclose
 
Subba R Digumarthy
No Relationships to Disclose
 
Mizuki Nishino
Honoraria - Roche Pharma AG
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst); Merck (Inst); Toshiba (Inst)
 
Lynette M. Sholl
Honoraria - AstraZeneca
Consulting or Advisory Role - Foghorn Therapeutics; Loxo
Research Funding - Roche/Genentech
 
Justin F. Gainor
Employment - Ironwood Pharmaceuticals (I)
Stock and Other Ownership Interests - Ironwood Pharmaceuticals (I)
Honoraria - ARIAD; Incyte; Merck; Novartis; Pfizer; Takeda
Consulting or Advisory Role - Agios; Amgen; Array BioPharma; Blueprint Medicines; Bristol-Myers Squibb; Genentech; Gilead Sciences; Jounce Therapeutics; Lilly; Loxo; Merck; Moderna Therapeutics; Oncorus; Regeneron; Takeda; Theravance
Research Funding - Adaptimmune (Inst); Alexo Therapeutics (Inst); ARIAD; Array BioPharma (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Genentech; Jounce Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Tesaro (Inst)
 
Matthew David Hellmann
Stock and Other Ownership Interests - Immunai; Shattuck Labs
Honoraria - AstraZeneca; Bristol-Myers Squibb
Consulting or Advisory Role - AstraZeneca/MedImmune; Blueprint Medicines; Bristol-Myers Squibb; Genentech; Immunai; Merck; Mirati Therapeutics; Nektar; Shattuck Labs; Syndax
Research Funding - Bristol-Myers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - A patent has been filed by Memorial Sloan Kettering (PCT/US2015/062208) for the use of tumor mutation burden for prediction of immunotherapy efficacy, and which is licensed to Personal Genome Diagnostics. (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb
 
Mark M. Awad
Consulting or Advisory Role - Abbvie; Achilles Therapeutics; ARIAD; AstraZeneca/MedImmune; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Foundation Medicine; Genentech; Gritstone Bio; Hengrui Therapeutics; Maverick Therapeutics; Merck; Nektar; Neon Therapeutics; Novartis; Pfizer; Syndax
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst)